DOR BioPharma Revenue and Competitors
Estimated Revenue & Valuation
- DOR BioPharma's estimated annual revenue is currently $7.1M per year.
- DOR BioPharma's estimated revenue per employee is $155,000
Employee Data
- DOR BioPharma has 46 Employees.
- DOR BioPharma grew their employee count by 0% last year.
DOR BioPharma's People
| Name | Title | Email/Phone |
|---|
DOR BioPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $9.1M | 59 | -9% | N/A | N/A |
#10 | $16.6M | 107 | 3% | N/A | N/A |
What Is DOR BioPharma?
DOR BioPharma, Inc. ( DOR ) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR’s lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation.
keywords:N/A
N/A
Total Funding
46
Number of Employees
$7.1M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.9M | 46 | -8% | N/A |
#2 | $9.9M | 46 | 5% | N/A |
#3 | $5.3M | 46 | -13% | N/A |
#4 | $9.9M | 46 | -15% | N/A |
#5 | $12.1M | 46 | 0% | N/A |